Citadel Advisors
INO icon

Citadel Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Citadel Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Buy
61,900
+17,000
+38% +$28K ﹤0.01% 11947
2025
Q4 		$78.1K Buy
44,900
+33,800
+305% +$74.5K ﹤0.01% 11810
2025
Q3 		$26K Sell
11,100
-13,000
-54% -$24.9K ﹤0.01% 12434
2025
Q2 		$49K Buy
24,100
+2,700
+13% +$5.17K ﹤0.01% 11776
2025
Q1 		$34.9K Sell
21,400
-5,760
-21% -$11.6K ﹤0.01% 12667
2024
Q4 		$49.7K Sell
27,160
-15,508
-36% -$68.6K ﹤0.01% 12398
2024
Q3 		$247K Buy
42,668
+4,520
+12% +$37.3K ﹤0.01% 9711
2024
Q2 		$308K Sell
38,148
-19,172
-33% -$202K ﹤0.01% 9083
2024
Q1 		$796K Buy
57,320
+54,653
+2,049% +$472K ﹤0.01% 7408
2023
Q4 		$16.3K Buy
2,667
+425
+19% +$2.1K ﹤0.01% 12798
2023
Q3 		$10.5K Buy
2,242
+609
+37% +$3.36K ﹤0.01% 13059
2023
Q2 		$8.75K Sell
1,633
-8,284
-84% -$66.8K ﹤0.01% 13298
2023
Q1 		$97.6K Sell
9,917
-29,283
-75% -$499K ﹤0.01% 11302
2022
Q4 		$734K Sell
39,200
-9,375
-19% -$212K ﹤0.01% 7437
2022
Q3 		$1.01M Buy
48,575
+1,158
+2% +$29.6K ﹤0.01% 6980
2022
Q2 		$984K Buy
47,417
+31,775
+203% +$896K ﹤0.01% 7049
2022
Q1 		$674K Sell
15,642
-20,433
-57% -$920K ﹤0.01% 8663
2021
Q4 		$2.16M Sell
36,075
-41,100
-53% -$3.29M ﹤0.01% 6058
2021
Q3 		$6.63M Buy
77,175
+32,350
+72% +$3.25M ﹤0.01% 3773
2021
Q2 		$4.99M Sell
44,825
-39,050
-47% -$3.75M ﹤0.01% 4439
2021
Q1 		$9.34M Buy
83,875
+4,533
+6% +$596K ﹤0.01% 3072
2020
Q4 		$8.43M Sell
79,342
-4,983
-6% -$663K ﹤0.01% 2871
2020
Q3 		$11.7M Sell
84,325
-1,283
-1% -$268K ﹤0.01% 2101
2020
Q2 		$27.7M Buy
85,608
+57,400
+203% +$9.22M 0.01% 1219
2020
Q1 		$2.52M Buy
28,208
+27,050
+2,336% +$1.67M ﹤0.01% 3773
2019
Q4 		$46K Buy
+1,158
New +$34.9K ﹤0.01% 8779
2019
Q1 		– Sell
-2,733
Closed -$131K – 9563
2018
Q4 		$131K Sell
2,733
-1,267
-32% -$77K ﹤0.01% 8126
2018
Q3 		$267K Buy
4,000
+383
+11% +$21.3K ﹤0.01% 7768
2018
Q2 		$170K Buy
3,617
+1,309
+57% +$72.2K ﹤0.01% 8002
2018
Q1 		$130K Buy
2,308
+683
+42% +$37K ﹤0.01% 7610
2017
Q4 		$81K Buy
1,625
+625
+63% +$38.7K ﹤0.01% 7497
2017
Q3 		$76K Sell
1,000
-17
-2% -$1.26K ﹤0.01% 7105
2017
Q2 		$96K Buy
+1,017
New +$87K ﹤0.01% 6920
2017
Q1 		– Sell
-1,467
Closed -$122K – 7735
2016
Q4 		$122K Buy
1,467
+517
+54% +$46.7K ﹤0.01% 6594
2016
Q3 		$106K Sell
950
-2,317
-71% -$256K ﹤0.01% 6632
2016
Q2 		$362K Buy
+3,267
New +$397K ﹤0.01% 4945
2016
Q1 		– Sell
-708
Closed -$57K – 7327
2015
Q4 		$57K Sell
708
-192
-21% -$15.3K ﹤0.01% 7200
2015
Q3 		$62K Sell
900
-17
-2% -$1.48K ﹤0.01% 7417
2015
Q2 		$90K Buy
917
+75
+9% +$8.01K ﹤0.01% 7179
2015
Q1 		$82K Buy
842
+284
+51% +$27.5K ﹤0.01% 7003
2014
Q4 		$62K Sell
558
-809
-59% -$98.9K ﹤0.01% 7032
2014
Q3 		$162K Buy
1,367
+92
+7% +$11.5K ﹤0.01% 5944
2014
Q2 		$165K Buy
1,275
+1,050
+467% +$124K ﹤0.01% 5768
2014
Q1 		$36K Buy
+225
New +$32.3K ﹤0.01% 6982

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's INO Position: Q1 2026 in Review

Citadel Advisors opened a new position in Inovio Pharmaceuticals (INO) in Q1 2026: 286,352 shares worth $498K. The stake represents ﹤0.01% of the portfolio and ranks #9323 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INO as recently as Q3 2025.

Citadel Advisors first reported a position in INO in Q4 2013 and has held it in 32 quarters since. The position peaked at $9.29M in Q1 2021. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Citadel Advisors held 286,352 shares of Inovio Pharmaceuticals worth $498K as of Q1 2026.
  • Inovio Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9323 holding.
  • Citadel Advisors first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 32 quarters since.
  • Citadel Advisors's Inovio Pharmaceuticals position peaked at $9.29M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.